EdgarLookup

Vystar Corp — Financial Data

Annual figures from SEC EDGAR XBRL filings (10-K)

These figures are extracted directly from XBRL-tagged financial statements that Vystar Corp filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.

Overview All Filings Annual Quarterly Insiders
-447.8%
Profit Margin
Net income ÷ revenue
-338.5%
Return on Assets
Net income ÷ assets
-0.9x
Debt-to-Equity
Total liabilities ÷ equity
+1941.6%
Revenue Growth
Year over year

Revenue

Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.

Fiscal Year Period End Value Filed
FY2018 Dec 31, 2018 $342.0K Apr 23, 2019
FY2018 Dec 31, 2017 $16.8K Apr 23, 2019
FY2017 Dec 31, 2016 $40.2K Mar 29, 2018
FY2016 Dec 31, 2015 $47.3K Apr 14, 2017
FY2015 Dec 31, 2014 $651.0K Apr 14, 2016
FY2014 Dec 31, 2013 $332.7K Apr 15, 2015
FY2013 Dec 31, 2012 $540.2K Jun 4, 2014

Revenue

Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $54.8K Apr 15, 2026
FY2025 Dec 31, 2024 $136.0K Apr 15, 2026
FY2024 Dec 31, 2023 $525.9K Apr 14, 2025
FY2023 Dec 31, 2022 $116.5K Sep 6, 2024
FY2022 Dec 31, 2021 $1.67M Oct 10, 2023
FY2021 Dec 31, 2020 $20.98M May 17, 2022
FY2020 Dec 31, 2019 $13.69M Apr 16, 2021
FY2019 Dec 31, 2018 $342.0K Jul 7, 2020

Gross Profit

Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $31.8K Apr 15, 2026
FY2025 Dec 31, 2024 $69.6K Apr 15, 2026
FY2024 Dec 31, 2023 $384.6K Apr 14, 2025
FY2023 Dec 31, 2022 ($388.7K) Sep 6, 2024
FY2022 Dec 31, 2021 ($241.9K) Oct 10, 2023
FY2021 Dec 31, 2020 $10.97M May 17, 2022
FY2020 Dec 31, 2019 $6.35M Apr 16, 2021
FY2019 Dec 31, 2018 ($43.8K) Jul 7, 2020
FY2018 Dec 31, 2017 ($4.7K) Apr 23, 2019
FY2017 Dec 31, 2016 $19.7K Mar 29, 2018

Net Income

The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 ($1.53M) Apr 15, 2026
FY2025 Dec 31, 2024 $759.5K Apr 15, 2026
FY2024 Dec 31, 2023 ($5.24M) Apr 14, 2025
FY2023 Dec 31, 2022 ($3.96M) Sep 6, 2024
FY2022 Dec 31, 2021 ($2.70M) Oct 10, 2023
FY2021 Dec 31, 2020 ($7.61M) May 17, 2022
FY2020 Dec 31, 2019 ($7.70M) Apr 16, 2021
FY2019 Dec 31, 2018 ($5.40M) Jul 7, 2020
FY2018 Dec 31, 2017 ($1.18M) Apr 23, 2019
FY2017 Dec 31, 2016 ($1.22M) Mar 29, 2018

Operating Income

Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 ($1.06M) Apr 15, 2026
FY2025 Dec 31, 2024 ($1.52M) Apr 15, 2026
FY2024 Dec 31, 2023 ($1.54M) Apr 14, 2025
FY2023 Dec 31, 2022 ($2.95M) Sep 6, 2024
FY2022 Dec 31, 2021 ($3.80M) Oct 10, 2023
FY2021 Dec 31, 2020 ($4.84M) May 17, 2022
FY2020 Dec 31, 2019 ($4.94M) Apr 16, 2021
FY2019 Dec 31, 2018 ($3.72M) Jul 7, 2020
FY2018 Dec 31, 2017 ($1.13M) Apr 23, 2019
FY2017 Dec 31, 2016 ($1.08M) Mar 29, 2018

R&D Expense

Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.

Fiscal Year Period End Value Filed
FY2024 Dec 31, 2023 $100.0K Apr 14, 2025
FY2018 Dec 31, 2018 $2.40M Apr 23, 2019
FY2014 Dec 31, 2014 $0 Apr 15, 2015
FY2014 Dec 31, 2013 $22.2K Apr 15, 2015
FY2013 Dec 31, 2012 $37.0K Jun 4, 2014
FY2012 Dec 31, 2011 $68.4K Jun 20, 2013
FY2011 Dec 31, 2010 $70.6K Mar 30, 2012

Operating Cash Flow

Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 ($180.4K) Apr 15, 2026
FY2025 Dec 31, 2024 ($100.0K) Apr 15, 2026
FY2024 Dec 31, 2023 ($442.7K) Apr 14, 2025
FY2023 Dec 31, 2022 ($515.5K) Sep 6, 2024
FY2022 Dec 31, 2021 ($2.86M) Oct 10, 2023
FY2021 Dec 31, 2020 ($2.26M) May 17, 2022
FY2020 Dec 31, 2019 ($1.51M) Apr 16, 2021
FY2019 Dec 31, 2018 ($1.51M) Jul 7, 2020
FY2018 Dec 31, 2017 ($499.0K) Apr 23, 2019
FY2017 Dec 31, 2016 ($907.4K) Mar 29, 2018

Capital Expenditures (Capex)

Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.

Fiscal Year Period End Value Filed
FY2021 Dec 31, 2021 $115.4K May 17, 2022
FY2021 Dec 31, 2020 $130.2K May 17, 2022

Total Assets

The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $452.5K Apr 15, 2026
FY2025 Dec 31, 2024 $553.3K Apr 15, 2026
FY2024 Dec 31, 2023 $712.4K Apr 14, 2025
FY2023 Dec 31, 2022 $11.64M Sep 6, 2024
FY2022 Dec 31, 2021 $16.86M Oct 10, 2023
FY2021 Dec 31, 2020 $22.66M May 17, 2022
FY2020 Dec 31, 2019 $22.40M Apr 16, 2021
FY2019 Dec 31, 2018 $2.47M Jul 7, 2020
FY2018 Dec 31, 2017 $307.4K Apr 23, 2019
FY2017 Dec 31, 2016 $234.5K Mar 29, 2018

Total Liabilities

All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.

Fiscal Year Period End Value Filed
FY2024 Dec 31, 2024 $5.84M Apr 14, 2025
FY2024 Dec 31, 2023 $9.75M Apr 14, 2025
FY2023 Dec 31, 2022 $12.36M Sep 6, 2024
FY2022 Dec 31, 2021 $22.76M Oct 10, 2023
FY2021 Dec 31, 2020 $29.42M May 17, 2022
FY2020 Dec 31, 2019 $23.63M Apr 16, 2021
FY2019 Dec 31, 2018 $4.34M Jul 7, 2020
FY2018 Dec 31, 2017 $3.16M Apr 23, 2019
FY2017 Dec 31, 2016 $3.06M Mar 29, 2018
FY2016 Dec 31, 2015 $3.04M Apr 14, 2017

Stockholders Equity

The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 ($6.51M) Apr 15, 2026
FY2025 Dec 31, 2024 ($5.26M) Apr 15, 2026
FY2024 Dec 31, 2023 ($7.25M) Apr 14, 2025
FY2023 Dec 31, 2022 ($2.01M) Sep 6, 2024
FY2022 Dec 31, 2021 ($7.56M) Oct 10, 2023
FY2021 Dec 31, 2020 ($7.36M) May 17, 2022
FY2020 Dec 31, 2019 ($2.56M) Apr 16, 2021
FY2019 Dec 31, 2018 ($1.87M) Jul 7, 2020
FY2018 Dec 31, 2017 ($2.86M) Apr 23, 2019
FY2018 Dec 31, 2016 ($2.82M) Apr 23, 2019

Goodwill

An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.

Fiscal Year Period End Value Filed
FY2022 Dec 31, 2021 $147.1K Oct 10, 2023
FY2021 Dec 31, 2020 $460.3K May 17, 2022
FY2020 Dec 31, 2019 $460.3K Apr 16, 2021
FY2020 Jul 18, 2019 $313.2K Apr 16, 2021
FY2019 Dec 31, 2018 $147.1K Jul 7, 2020
FY2014 Dec 31, 2014 $106.0K Apr 15, 2015
FY2012 Dec 31, 2012 $68.0K Jun 20, 2013

Retained Earnings

Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 ($61.38M) Apr 15, 2026
FY2025 Dec 31, 2024 ($59.85M) Apr 15, 2026
FY2024 Dec 31, 2023 ($60.61M) Apr 14, 2025
FY2023 Dec 31, 2022 ($55.37M) Sep 6, 2024
FY2022 Dec 31, 2021 ($51.41M) Oct 10, 2023
FY2021 Dec 31, 2020 ($48.71M) May 17, 2022
FY2020 Dec 31, 2019 ($41.10M) Apr 16, 2021
FY2019 Dec 31, 2018 ($33.40M) Jul 7, 2020
FY2018 Dec 31, 2017 ($28.00M) Apr 23, 2019
FY2017 Dec 31, 2016 ($26.81M) Mar 29, 2018

Cash & Equivalents

Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.

Fiscal Year Period End Value Filed
FY2014 Dec 31, 2014 $73.8K Apr 15, 2015
FY2014 Dec 31, 2013 $56.4K Apr 15, 2015
FY2014 Dec 31, 2012 $91.9K Apr 15, 2015
FY2013 Dec 31, 2011 $16.7K Jun 4, 2014
FY2012 Dec 31, 2010 $282.6K Jun 20, 2013
FY2011 Dec 31, 2009 $780.1K Mar 30, 2012

Long-Term Debt

Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.

Fiscal Year Period End Value Filed
FY2021 Dec 31, 2021 $4.28M May 17, 2022
FY2020 Dec 31, 2020 $2.04M Apr 16, 2021
FY2020 Dec 31, 2019 $1.71M Apr 16, 2021
FY2017 Dec 31, 2017 $881.7K Mar 29, 2018
FY2014 Dec 31, 2014 $0 Apr 15, 2015
FY2014 Dec 31, 2013 $83.7K Apr 15, 2015
FY2013 Dec 31, 2012 $184.7K Jun 4, 2014

EPS (Basic)

Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.

Fiscal Year Period End Value Filed
FY2021 Dec 31, 2021 0 May 17, 2022
FY2021 Dec 31, 2020 0 May 17, 2022

Shares Outstanding

Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 24.62M Apr 15, 2026
FY2025 Dec 31, 2024 17.40M Apr 15, 2026
FY2024 Dec 31, 2023 12.94M Apr 14, 2025
FY2023 Dec 31, 2022 12.94M Sep 6, 2024
FY2022 Dec 31, 2021 12.94M Oct 10, 2023
FY2021 Dec 31, 2020 1.12B May 17, 2022
FY2020 Dec 31, 2019 1.11B Apr 16, 2021
FY2019 Dec 31, 2018 457.75M Jul 7, 2020
FY2018 Dec 31, 2017 132.81M Apr 23, 2019
FY2017 Dec 31, 2016 114.95M Mar 29, 2018